N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer
Background Programmed death-1 (PD-1) checkpoint blockade has revolutionized cancer therapy, yet its clinical success is confined to a subset of patients, underscoring the urgent need to understand the molecular underpinnings of programmed cell death ligand 1 (PD-L1) expression to combat immunotherap...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/11/e009905.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846121577017507840 |
|---|---|
| author | Xing Gao Xiang He Yongshuo Liu Feiyu Tang Yuxi Tian Siyuan Gong Jia Shen Aimin Wang Lunquan Sun Wensheng Wei Liang Weng |
| author_facet | Xing Gao Xiang He Yongshuo Liu Feiyu Tang Yuxi Tian Siyuan Gong Jia Shen Aimin Wang Lunquan Sun Wensheng Wei Liang Weng |
| author_sort | Xing Gao |
| collection | DOAJ |
| description | Background Programmed death-1 (PD-1) checkpoint blockade has revolutionized cancer therapy, yet its clinical success is confined to a subset of patients, underscoring the urgent need to understand the molecular underpinnings of programmed cell death ligand 1 (PD-L1) expression to combat immunotherapy resistance.Methods Employing CRISPR/Cas9 screening, we identified key regulators of PD-L1 in non-small cell lung cancer (NSCLC) cells, focusing on the transcription factor CEBPB and its isoform liver-enriched inhibitory protein (LIP). Through chromatin immunoprecipitation (ChIP) and luciferase reporter assays, we explored the interaction between LIP and basic-helix-loop-helix E22 (BHLHE22) in controlling PD-L1 transcription. We also used immunofluorescence and NBD-CI assays to examine how N-terminal acetylation affects LIP’s subcellular localization. The impact of LIP on tumor growth was assessed via subcutaneous tumorigenicity assays, while immunohistochemistry and immunofluorescence were used to analyze LIP-induced alterations in the tumor immune microenvironment.Results Our research indicates that CEBPB, particularly its LIP isoform, significantly suppresses PD-L1 expression in NSCLC cells. This suppression is contingent on LIP’s N-terminal acetylation by the N-terminal acetyltransferase A complex, which facilitates LIP’s nuclear entry and interaction with BHLHE22. This interaction leads to the formation of a co-repressor complex at the PD-L1 promoter, effectively reducing PD-L1 expression and enhancing the tumor immune response.Conclusions Identifying CEBPB, especially the LIP isoform, as a pivotal regulator of PD-L1 expression sheds light on the mechanisms behind PD-1 blockade resistance in NSCLC. Our findings suggest that modulating LIP’s function or its molecular interactions might offer a novel approach to boosting the efficacy of immunotherapies. |
| format | Article |
| id | doaj-art-6bea76d1a64e4fdd9e9b1d5e40cd0014 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-6bea76d1a64e4fdd9e9b1d5e40cd00142024-12-15T23:30:11ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-11-01121110.1136/jitc-2024-009905N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancerXing Gao0Xiang He1Yongshuo Liu2Feiyu Tang3Yuxi Tian4Siyuan Gong5Jia Shen6Aimin Wang7Lunquan Sun8Wensheng Wei9Liang Weng10Center of Oral and Maxillofacial Cancer (COMAC), Xiangya Hospital Central South University, Changsha, Hunan, ChinaKey Laboratory of Molecular Radiation Oncology Hunan Province, Xiangya Cancer Center, Xiangya Hospital Central South University, Changsha, ChinaDepartment of Pathology and Lab Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaCenter for Biotherapy, Sun Yat-Sen University, Guangzhou, ChinaDepartment of Geriatric Respiratory and Critical Care Medicine, Xiangya Hospital Central South University, Changsha, Hunan, ChinaKey Laboratory of Molecular Radiation Oncology Hunan Province, Xiangya Cancer Center, Xiangya Hospital Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha, ChinaDepartment of Emergency, Xiangya Hospital Central South University, Changsha, ChinaKey Laboratory of Molecular Radiation Oncology Hunan Province, Xiangya Cancer Center, Xiangya Hospital Central South University, Changsha, ChinaBiomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Laboratory of Protein and Plant Gene Research, Peking University School of Life Sciences, Beijing, ChinaDepartment of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing, ChinaBackground Programmed death-1 (PD-1) checkpoint blockade has revolutionized cancer therapy, yet its clinical success is confined to a subset of patients, underscoring the urgent need to understand the molecular underpinnings of programmed cell death ligand 1 (PD-L1) expression to combat immunotherapy resistance.Methods Employing CRISPR/Cas9 screening, we identified key regulators of PD-L1 in non-small cell lung cancer (NSCLC) cells, focusing on the transcription factor CEBPB and its isoform liver-enriched inhibitory protein (LIP). Through chromatin immunoprecipitation (ChIP) and luciferase reporter assays, we explored the interaction between LIP and basic-helix-loop-helix E22 (BHLHE22) in controlling PD-L1 transcription. We also used immunofluorescence and NBD-CI assays to examine how N-terminal acetylation affects LIP’s subcellular localization. The impact of LIP on tumor growth was assessed via subcutaneous tumorigenicity assays, while immunohistochemistry and immunofluorescence were used to analyze LIP-induced alterations in the tumor immune microenvironment.Results Our research indicates that CEBPB, particularly its LIP isoform, significantly suppresses PD-L1 expression in NSCLC cells. This suppression is contingent on LIP’s N-terminal acetylation by the N-terminal acetyltransferase A complex, which facilitates LIP’s nuclear entry and interaction with BHLHE22. This interaction leads to the formation of a co-repressor complex at the PD-L1 promoter, effectively reducing PD-L1 expression and enhancing the tumor immune response.Conclusions Identifying CEBPB, especially the LIP isoform, as a pivotal regulator of PD-L1 expression sheds light on the mechanisms behind PD-1 blockade resistance in NSCLC. Our findings suggest that modulating LIP’s function or its molecular interactions might offer a novel approach to boosting the efficacy of immunotherapies.https://jitc.bmj.com/content/12/11/e009905.full |
| spellingShingle | Xing Gao Xiang He Yongshuo Liu Feiyu Tang Yuxi Tian Siyuan Gong Jia Shen Aimin Wang Lunquan Sun Wensheng Wei Liang Weng N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer Journal for ImmunoTherapy of Cancer |
| title | N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer |
| title_full | N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer |
| title_fullStr | N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer |
| title_full_unstemmed | N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer |
| title_short | N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer |
| title_sort | n terminal acetylation of transcription factor lip induces immune therapy resistance via suppression of pd l1 expression in non small cell lung cancer |
| url | https://jitc.bmj.com/content/12/11/e009905.full |
| work_keys_str_mv | AT xinggao nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT xianghe nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT yongshuoliu nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT feiyutang nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT yuxitian nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT siyuangong nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT jiashen nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT aiminwang nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT lunquansun nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT wenshengwei nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer AT liangweng nterminalacetylationoftranscriptionfactorlipinducesimmunetherapyresistanceviasuppressionofpdl1expressioninnonsmallcelllungcancer |